Third generation EGFR TKIs: current data and future directions

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Acquired T790M mutations are the primary cause of resistance in advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations after first-line EGFR tyrosine kinase inhibitor (TKI) therapy.
• Third-generation EGFR TKIs, designed for EGFR mutant selectivity and wild-type sparing, are developed to overcome T790M-mediated resistance.
• Osimertinib represents a leading third-generation EGFR TKI in clinical development.

Purpose of the Study:

• To review the mechanisms of acquired resistance to third-generation EGFR TKIs in NSCLC.
• To discuss emerging treatment options for patients who progress on third-generation EGFR TKIs.
• To highlight the potential of Osimertinib as a first-line treatment based on FLAURA study findings.

Main Methods:

• Literature review of acquired resistance mechanisms to EGFR TKIs in NSCLC.
• Analysis of clinical trial data, including the FLAURA study for Osimertinib.
• Discussion of ongoing research into novel therapeutic strategies.

Main Results:

• The C797S mutation in exon 20 is identified as a common mechanism of acquired resistance to third-generation EGFR TKIs.
• Despite initial efficacy, acquired resistance necessitates the development of novel treatment approaches.
• The FLAURA study demonstrated improved progression-free survival with Osimertinib compared to first-generation EGFR TKIs in the first-line setting.

Conclusions:

• Acquired resistance, particularly C797S mutations, remains a significant challenge in EGFR-mutant NSCLC treatment.
• Novel therapies are under development for patients resistant to third-generation EGFR TKIs.
• Osimertinib is poised to become a new standard of care for first-line treatment of advanced NSCLC.